Swiss Life Science Startup EraCal closed oversubscribed seed round

EraCal closed oversubscribed seed round

October 2019

EraCal announced:

“EraCal joins forces with Bernina BioInvest, Redalpine, Life Sciences Fund and private investors to bring first-in-class medicines to patients. We are very grateful for their support of EraCal’s innovative research strategy! This seed investment enables the preclinical development of Era-107, our lead appetite suppressor with remarkable in vivo potency and selectivity, and a platform expansion to new indications.”


Image: J. Jordi Ph.D., Chief Executive Officer and S. Breitler Ph.D., Chief Operational Officer © EraCal Therapeutics


Der Weg zur emissionsfreien Schifffahrt
Fintech Dreams sammelt neun Millionen Euro ein und expandiert nach Deutschland

Ähnliche Beiträge